A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma.

ABSTRACT:

Background

To demonstrate the potential value of ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) as a rapid, non-invasive metabolic imaging surrogate for pharmacological modulation of EGFR signaling in EGFR-driven GBM, we synchronously conducted a preclinical imaging study using patient-derived orthotopic xenograft (PDOX) models and validated it in a phase II molecular imaging study in recurrent GBM (rGBM) patients using osimertinib.

Methods

A GBM PDOX mouse model study was performed concurrently with an open-label, single-arm, single-center, phase II study of osimertinib (NCT03732352) that enrolled 12 patients with rGBM with EGFR alterations. Patients received osimertinib daily and 3 ¹⁸F-FDG PET scans: two 24 h apart prior

SUBMITTER: Ellingson BM 

PROVIDER: S-EPMC11883343 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature